Half-Life Cancer Research Results

Half-Life, Half-Life: Click to Expand ⟱
Source:
Type:
For many drugs, the half-life is the time it takes for half of the drug’s active substance to be eliminated from the bloodstream.
In medicine, knowing a drug’s half-life helps in designing treatment regimens that reduce adverse effects.


Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy

Scientific Papers found: Click to Expand⟱
5291- 5-HTP,    Kinetics of l-5-hydroxytryptophan in healthy subjects
- in-vivo, Nor, NA
*Half-Life↝, *BioAv↑,
5456- AF,    Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent
- Trial, Nor, NA
*Dose?, *Half-Life↝, *Dose↑, *toxicity↝, *Bacteria↓, *Dose↑,
5443- AG,    Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers
- Human, Nor, NA
*Dose↝, Half-Life↝, *toxicity↓,
4600- AgNPs,    Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model
- in-vivo, Nor, NA
*Half-Life↝, *toxicity↓, *Dose↑, *other↝, *eff↝, *BioAv↓,
5322- ALC,    Comparison of pharmacokinetics of L-carnitine, Acetyl-L-carnitine and Propionyl-Lcarnitine after single oral administration of L-carnitine in healthy volunteers
- Human, Nor, NA
*Half-Life↝,
2569- ART/DHA,    A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction
- Human, Nor, NA
*Half-Life↝, BioAv↝, *Half-Life↓, BioAv↑, *Dose↝,
5423- ASTX,    Pharmacokinetic Profile of Astaxanthin Nanoemulsion Using HPLC (High-Performance Liquid Chromatography) With Oral Routes
- in-vivo, Nor, NA
*BioAv↓, *antiOx↑, *BioAv↑, *Half-Life↝,
5445- ATV,    Atorvastatin
- NA, Nor, NA
*cardioP↑, *LDL↓, HMG-CoA↓, Half-Life↝, BioAv↓, Dose↝,
5500- Ba,    Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single‐center, randomized, double‐blind, placebo‐controlled multiple‐ascending‐dose study
- Trial, Nor, NA
*toxicity↓, *BioAv↑, *Half-Life↝, *Dose↝,
5654- BNL,    Pharmacokinetics of natural borneol after oral administration in mice brain and its effect on excitation ratio
- in-vivo, Nor, NA
*BioAv↑, *Half-Life↝, other↝,
5669- BNL,    Comparison of pharmacological activity and safety of different stereochemical configurations of borneol: L-borneol, D-borneol, and synthetic borneol
- Review, Nor, NA - Review, AD, NA - Review, Stroke, NA
*eff↑, *eff↑, *toxicity↝, *Inflam↓, *Bacteria↓, *neuroP↑, *Half-Life↝, *BBB↑, *BioEnh↑, *P-gp↓, *CYP3A4↓, *ROS↓, *neuroP↑,
5672- Bor,    A comparative review of the pharmacokinetics of boric acid in rodents and humans
- in-vivo, Nor, NA
*Half-Life↝,
5879- CAR,    Pharmacokinetic analysis of thymol, carvacrol and diallyl disulfide after intramammary and topical applications in healthy organic dairy cattle
- in-vivo, Nor, NA
*Dose↝, Half-Life↝, Half-Life↝, Half-Life↝,
6029- CGA,    Pharmacokinetics of chlorogenic acids absorbed in human plasma and their metabolites following oral ingestion of coffee drink
- Trial, Nor, NA
*Dose↝, *BioAv↑, *Half-Life↝,
2809- CUR,    Comparative absorption of curcumin formulations
- in-vivo, Nor, NA
BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↓, Half-Life↝,
2561- EGCG,  ASA,    Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment
- ex-vivo, Nor, NA
AntiAg↑, eff↑, Half-Life↝, other∅,
2442- RES,    High absorption but very low bioavailability of oral resveratrol in humans
- in-vitro, Nor, NA
BioAv↝, Half-Life↝, BioAv↓, eff↝,
3019- RosA,    Orally administered rosmarinic acid is present as the conjugated and/or methylated forms in plasma, and is degraded and metabolized to conjugated forms of caffeic acid, ferulic acid and m-coumaric acid
- in-vivo, Nor, NA
*BioAv↝, *Half-Life↝, *Half-Life↑, *Half-Life↝, *BioAv↑,
3291- SIL,    Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases
- Review, Nor, NA
*antiOx↑, *ROS↓, *cardioP↑, *BioAv↓, *Half-Life↝, *other↑, IronCh↑,

Showing Research Papers: 1 to 19 of 19

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 19

Pathway results for Effect on Cancer / Diseased Cells:


Metal & Cofactor Biology

IronCh↑, 1,  

Core Metabolism/Glycolysis

HMG-CoA↓, 1,  

Transcription & Epigenetics

other↝, 1,   other∅, 1,  

Migration

AntiAg↑, 1,  

Drug Metabolism & Resistance

BioAv↓, 3,   BioAv↑, 6,   BioAv↝, 2,   Dose↝, 1,   eff↑, 1,   eff↝, 1,   Half-Life↝, 8,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 2,   ROS↓, 2,  

Core Metabolism/Glycolysis

CYP3A4↓, 1,   LDL↓, 1,  

Transcription & Epigenetics

other↑, 1,   other↝, 1,  

Barriers & Transport

BBB↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling

Inflam↓, 1,  

Drug Metabolism & Resistance

BioAv↓, 3,   BioAv↑, 6,   BioAv↝, 1,   BioEnh↑, 1,   Dose?, 1,   Dose↑, 3,   Dose↝, 5,   eff↑, 2,   eff↝, 1,   Half-Life↓, 1,   Half-Life↑, 1,   Half-Life↝, 14,  

Functional Outcomes

cardioP↑, 2,   neuroP↑, 2,   toxicity↓, 3,   toxicity↝, 2,  

Infection & Microbiome

Bacteria↓, 2,  
Total Targets: 26

Scientific Paper Hit Count for: Half-Life, Half-Life
2 borneol
1 5-Hydroxytryptophan
1 Auranofin
1 Astragalus
1 Silver-NanoParticles
1 Acetyl-l-carnitine
1 Artemisinin
1 Astaxanthin
1 Atorvastatin
1 Baicalein
1 Boron
1 Carvacrol
1 Chlorogenic acid
1 Curcumin
1 EGCG (Epigallocatechin Gallate)
1 Aspirin -acetylsalicylic acid
1 Resveratrol
1 Rosmarinic acid
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:1109  State#:%  Dir#:4
wNotes=0 sortOrder:rid,rpid

 

Home Page